Turk J Hematol 2018;35:75-93 LETTERS TO THE EDITOR

t(9;19)(q22;p13) in Acute Myelomonocytic Leukemia

Akut Miyelomonositik Lösemide t(9;19)(q22;p13)

¹Tehran University Faculty of Medicine, Department of Pathology, Molecular Pathology and Cytogenetic Ward, Tehran, Iran ²Shiraz University of Faculty of Medicine, Department of Pathology, Molecular Pathology and Cytogenetic Ward, Shiraz, Iran

To the Editor,

Chromosomal aberrations play a role in the leukemogenesis of acute myeloid leukemia. Some chromosomal abnormalities such as t(8;21), t(15;17), and inv(16) are frequently observed, but hundreds of uncommon chromosomal translocations also exist and their significance remains to be clarified [1]. Here we introduce a case of acute myeloid leukemia with a very rare translocation and explain its morphologic and immunophenotyping findings.

The patient was a 50-year-old man with malaise and weakness. Paraclinical evaluation revealed leukocytosis along with anemia and thrombocytopenia (white blood cells: $24,000/\mu L$, hemoglobin: 7.4 g/dL, platelets: $30,000/\mu L$). Peripheral blood smear exhibited atypical blastoid cells. Subsequently the patient underwent bone marrow aspiration, which showed 80% blasts of myeloid and monocytic type with prominent cytoplasmic vacuolization. Immunophenotyping by flow cytometry revealed positive reactions for CD117, HLA-DR, MPO, and CD64. Morphologic

findings and immunophenotyping were compatible with acute myelomonocytic leukemia. Bone marrow cytogenetic study showed t(9;19)(q22;p13) (Figure 1). Reverse transcriptase PCR was performed for t(8;21) (*AML1-ETO* fusion gene) and inv(16) (*CBFB-MYH11* fusion gene), which was negative for both of them. *FLT3* duplication and *D835* mutation were also negative. Subsequently, the patient underwent a 7+3 chemotherapy regimen with cytarabine continuous infusion (300 mg, IV) over 24 h on days 1 to 7 and daunorubicin (115 mg, IV bolus) on days 1 to 3. Although remission was achieved after induction therapy (3% blasts in bone marrow 4 weeks after chemotherapy), unfortunately the patient contracted sepsis due to neutropenia and died 1.5 months after treatment initiation.

Acute myeloid leukemia with prominent monocytic lineage involvement (M4-M5) is usually associated with determined recurrent cytogenetic aberrations like inv(16), t(v;11) (*MLL* gene rearrangement), and t(8;16). According to a literature review, t(9;19)(q22;p13) has been reported previously only twice. The




Figure 1. Bone marrow karyotype study revealed t(9;19)(q22;p13).

LETTERS TO THE EDITOR

Turk J Hematol 2018;35:75-93

first case was a 57-year-old man with acute myelomonocytic leukemia and concomitant inv(16). Exact morphologic and immunophenotyping characteristics of this case were not determined [2]. The second case was a 13-year-old boy with acute myeloid leukemia (M0) who developed multiple clonal abnormalities during his treatment course [3]. The present case is the first patient with acute myelomonocytic leukemia with t(9;19) (q22;p13) as the sole chromosomal abnormality. This cytogenetic finding and its associated morphologic and immunophenotyping characteristics are noteworthy and merit attention.

Keywords: Acute myeloid leukemia, Cytogenetic, Monocytic differentiation

Anahtar Sözcükler: Akut miyeloid lösemi, Sitogenetik, Monositik farklılaşma

References

- Yang JJ, Park TS, Wan TSK. Recurrent cytogenetic abnormalities in acute myeloid leukemia. In: Wan TSK (ed). Cancer Cytogenetics. New York, Springer Nature, 2017.
- Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-449.
- Ostronoff F, Bueso-Ramos C, Cortes J, Giralt S. Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution. Am J Hematol 2007;82:744-747.



Address for Correspondence/Yazışma Adresi: Moeinadin SAFAVI, M.D., Tehran University Faculty of Medicine, Department of Pathology, Molecular Pathology and Cytogenetic Ward, Tehran, Iran

E-mail: safavi_moeinadin@yahoo.com ORCID-ID: orcid.org/0000-0002-4042-7506

Received/Geliş tarihi: October 07, 2017 Accepted/Kabul tarihi: December 28, 2017

DOI: 10.4274/tjh.2017.0368